Androgen deprivation and cognition in prostate cancer.
Androgen deprivation (AD) is commonly used in neoadjuvant and adjuvant setting with prostate cancer (PC) radiotherapy. This prospective study assessed whether cognitive functioning is impaired during 12 months of AD therapy. Longitudinal testing of 25 patients treated with AD and curative radiotherapy was undertaken at baseline, and at 6 and 12 months. CogniSpeed software was used for measuring attentional performances. Other cognitive performances were evaluated using verbal, visuomotor and memory tests. The Beck depression inventory was employed to evaluate depressive mood and EORTC QLQ-C30 for quality of life (QoL). During longitudinal testing of the AD group, no impairment in cognitive performances was found. Instead, improvement was observed in object recall (immediate, P=0.035; delayed, P<0.001), and in semantic memory (P=0.037). In QoL, impairment in physical function was observed. Androgen deprivation of 12 months appears to be associated with preserved cognitive functioning, although physical impairment occurs. These results have implications for counseling and psychosocial support of patients in the context of treatment options in PC.
Salminen
E
E
Department of Oncology, Turku University Hospital, Kiinamyllynkatu 4-8, Fin-20520 Turku, Finland. eevsal@utu.fi
Portin
R
R
Korpela
J
J
Backman
H
H
Parvinen
L-M
LM
Helenius
H
H
Nurmi
M
M
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D016022:Case-Control Studies; D003071:Cognition / Q000502:physiology*; D003131:Combined Modality Therapy; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011788:Quality of Life; D016896:Treatment Outcome
D000726:Androgen Antagonists